Who are fenoterol/ipratropium bromide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fenoterol-ipratropium-bromide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

fenoterol/ipratropium bromide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

fenoterol/ipratropium bromide (fenoterol/ipratropium bromide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-2 agonist / Anticholinergic combination bronchodilator. Area: Respiratory / Pulmonology.

marketed Beta-2 agonist / Anticholinergic combination bronchodilator Beta-2 adrenergic receptor (fenoterol); Muscarinic acetylcholine receptors (ipratropium bromide) Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

fenoterol/ipratropium bromide (fenoterol/ipratropium bromide) — Novartis. Fenoterol is a beta-2 agonist that relaxes airway smooth muscle, while ipratropium bromide is an anticholinergic that blocks acetylcholine-mediated bronchoconstriction, together providing dual bronchodilation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
fenoterol/ipratropium bromide TARGET	fenoterol/ipratropium bromide	Novartis	marketed	Beta-2 agonist / Anticholinergic combination bronchodilator	Beta-2 adrenergic receptor (fenoterol); Muscarinic acetylcholine receptors (ipratropium bromide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-2 agonist / Anticholinergic combination bronchodilator class)

Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fenoterol/ipratropium bromide — Competitive Intelligence Brief. https://druglandscape.com/ci/fenoterol-ipratropium-bromide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab